Wegovy Tablets Vs Injections

If you have been searching for Wegovy tablets, you are not alone — thousands of people across the UK are looking for a convenient pill form of this popular weight loss medication. The confusion is understandable, especially when so many headlines talk about Wegovy as a game-changing treatment. However, the reality of how Wegovy is actually available, and what your real options are in 2026, is something worth understanding clearly before you make any decisions about your health.

Quick Summary

Wegovy is a prescription semaglutide treatment licensed in the UK for weight management, but it is not available as a tablet — it comes as a once-weekly injection. Understanding the correct form, how it works, and what alternatives exist is essential before starting any treatment.

• Wegovy contains semaglutide, a GLP-1 receptor agonist that reduces appetite and slows gastric emptying
• There are currently no licensed Wegovy tablets available in the UK — the medication is administered as a subcutaneous injection
• Oral semaglutide exists under the brand name Rybelsus, but it is licensed for type 2 diabetes, not weight loss
• Other effective weight loss options include Mounjaro (tirzepatide) and Orlistat, available through registered UK prescribers
• You must meet specific clinical criteria to access Wegovy on prescription in the UK

Table of Contents

1. What Is Wegovy and Does a Tablet Form Actually Exist?
2. How Semaglutide Works for Weight Loss
3. Wegovy Tablets vs Injection: Understanding the Difference
4. Who Qualifies for Wegovy on Prescription in the UK?
5. Effective Weight Loss Alternatives Available in the UK
6. Common Side Effects and How to Manage Them
7. Comparison of UK Weight Loss Medications
8. Key Takeaways
9. When to Seek Professional Advice
10. Scientific References
11. Frequently Asked Questions

What Is Wegovy and Does a Tablet Form Actually Exist?

Wegovy is a prescription-only weight loss medication manufactured by Novo Nordisk. It contains semaglutide at a dose of 2.4mg and is licensed by the MHRA for chronic weight management in adults. It gained enormous attention in recent years and, as of 2026, remains one of the most clinically validated weight management treatments available in the UK. However, there is one point that consistently confuses people searching online: Wegovy tablets do not currently exist as a licensed UK weight loss product.

The medication is delivered via a pre-filled, once-weekly subcutaneous injection pen. You inject it into the fatty tissue of your abdomen, thigh, or upper arm. The injection pen is designed to be simple and discreet — many patients report feeling very comfortable with the process after the first few uses. If you are considering Wegovy tablets as a more convenient option, it is important to know the distinction between what is available, what is licensed, and what you might have seen referenced elsewhere online.

Oral semaglutide does exist — under the brand name Rybelsus — but this is licensed specifically for the management of type 2 diabetes in adults, not for weight loss. Its dosing and formulation differ significantly from Wegovy. Prescribing Rybelsus off-label purely for weight loss is not standard practice and would not be appropriate without careful clinical assessment.

• Wegovy contains semaglutide 2.4mg and is injected once weekly
• No licensed Wegovy tablet for weight loss currently exists in the UK
• Rybelsus is oral semaglutide but is indicated for type 2 diabetes only
• Any site claiming to sell Wegovy tablets for weight loss should be treated with extreme caution
• The injection pen is straightforward and designed for self-administration at home

How Semaglutide Works for Weight Loss

Semaglutide belongs to a class of medications known as GLP-1 receptor agonists. GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone released by the gut after eating. It plays a central role in regulating blood sugar levels and appetite. When semaglutide mimics this hormone at a much higher and more sustained level, it produces a powerful effect on how the brain perceives hunger and fullness. People taking Wegovy tablets — or more accurately, the Wegovy injection — typically find that they feel full after eating considerably smaller portions.

Beyond appetite suppression, semaglutide also slows gastric emptying, meaning food stays in the stomach for longer. This further contributes to a sense of satiety and helps reduce cravings throughout the day. The medication also acts on areas of the brain involved in reward-driven eating, which is why many users report a significant reduction in the compulsive urge to snack or eat for emotional reasons. This multi-pronged mechanism is what makes semaglutide so effective compared to older weight loss medications that simply suppressed hunger through stimulant pathways.

The landmark STEP clinical trials, which informed the MHRA licensing of Wegovy, demonstrated that participants lost an average of 14.9% of their body weight over 68 weeks compared to 2.4% in the placebo group. These results were unprecedented for a pharmacological weight loss treatment and helped change the conversation around obesity as a medical condition rather than a lifestyle failing.

• GLP-1 receptor agonists mimic a natural gut hormone that regulates hunger
• Semaglutide slows gastric emptying, keeping you feeling full for longer
• It also reduces reward-driven and emotional eating behaviours
• STEP trial data showed nearly 15% average body weight loss over 68 weeks
• The mechanism differs entirely from older stimulant-based appetite suppressants

Wegovy Tablets vs Injection: Understanding the Difference

The question of Wegovy tablets versus injections comes up constantly, and it is worth addressing directly because it touches on a genuine pain point for patients. Many people are uncomfortable with the idea of self-injecting, and it is entirely natural to feel that way at first. However, the reason Wegovy is formulated as an injection rather than an oral tablet is rooted in pharmacology. Semaglutide is a large peptide molecule that would be rapidly broken down by digestive enzymes and stomach acid if taken by mouth at the doses needed for weight management. The subcutaneous injection bypasses this degradation entirely, ensuring the medication reaches the bloodstream at full therapeutic strength.

Novo Nordisk has been working on oral formulations of semaglutide for weight loss, and research into higher-dose oral semaglutide was ongoing as of 2026. However, these have not yet received MHRA licensing for weight management specifically. If and when they do, they will represent a significant step forward in accessibility for patients who find injections difficult. For now, anyone who encounters websites advertising Wegovy tablets as a weight loss product should exercise considerable caution. Unregulated products sold online without a valid UK prescription carry serious health risks.

If needle anxiety is a genuine barrier for you, it is worth having an honest conversation with your prescriber. Many patients find that with proper guidance on injection technique, the process is far less daunting than anticipated. The Wegovy pen is extremely fine-gauged and most patients describe the injection as barely noticeable. Alternatives such as Mounjaro weight loss injections (tirzepatide) use a similarly small auto-injector pen and may also be suitable depending on your clinical profile.

• Semaglutide cannot be effectively absorbed in tablet form at weight loss doses due to digestive degradation
• Oral semaglutide research for weight loss is ongoing but no licensed tablet exists in the UK yet
• Fake or unregulated Wegovy tablet products online pose serious health and safety risks
• Injection anxiety is common but manageable — speak to your prescriber for guidance
• The Wegovy pen uses a very fine needle and most patients find self-injection straightforward

Who Qualifies for Wegovy on Prescription in the UK?

Access to Wegovy in the UK, whether via the NHS or a private prescriber, requires meeting specific clinical criteria. NICE guidelines, updated in recent years to reflect the growing evidence base for GLP-1 medications, set out clear thresholds for eligibility. This is not gatekeeping for its own sake — it reflects the importance of using this potent medication in patients who will genuinely benefit and for whom the risk-to-benefit profile is appropriate. Anyone searching for Wegovy tablets online in the hope of bypassing these criteria should be aware that doing so is both clinically unsafe and potentially illegal without a valid prescription.

In terms of NHS access, Wegovy is typically prescribed within specialist weight management services as part of a structured programme. Private prescribing is also available through registered UK services and platforms, including those offering online consultations with GPhC-registered pharmacists or GMC-registered doctors. The eligibility criteria include a BMI of 30 or above with at least one weight-related comorbidity, or a BMI of 35 or above without additional conditions. In some ethnic minority groups, lower BMI thresholds apply due to the increased cardiometabolic risk at lower body weights.

Before starting Wegovy, a thorough medical history review is essential. This includes screening for contraindications such as a personal or family history of medullary thyroid carcinoma, pancreatitis, or multiple endocrine neoplasia syndrome type 2. Women who are pregnant or planning a pregnancy are not suitable candidates. Your prescriber will also need to assess any concurrent medications to rule out interactions. If you are considering Orlos (orlistat) 60mg weight loss aid as an alternative, the eligibility criteria differ and it may be more accessible as an over-the-counter option for some patients.

• BMI of 30 or above with a weight-related health condition is typically required
• BMI of 35 or above may qualify without additional comorbidities
• Lower BMI thresholds apply for certain ethnic groups with higher cardiometabolic risk
• Contraindications include history of pancreatitis, medullary thyroid cancer, and pregnancy
• A medical consultation is mandatory — online or in-person — before any prescription is issued

Effective Weight Loss Alternatives Available in the UK

If Wegovy is not suitable for you, or if you are waiting for NHS access, there are several clinically validated alternatives worth knowing about. The weight management landscape in the UK has expanded considerably, and patients now have more choice than ever when it comes to medically supervised options. Understanding these alternatives helps you have a more informed conversation with your prescriber and reduces the temptation to seek unregulated products online — which remains a significant problem in 2026.

Mounjaro (tirzepatide) is currently generating considerable clinical interest as it targets both GLP-1 and GIP receptors simultaneously. Early comparative data suggests it may produce even greater weight loss than semaglutide in some patients, with trial data showing up to 20% or more body weight reduction in certain cohorts. It is available as a once-weekly injection pen and has gained MHRA approval for weight management in the UK. For those who prefer non-injectable options, XLS Medical Weight Loss Plus tablets provide an over-the-counter supplement option that can complement a calorie-controlled diet, though they work through an entirely different mechanism and are not prescription medications.

Orlistat remains the only licensed oral prescription weight loss medication in the UK. It works by inhibiting pancreatic lipase, preventing approximately one third of dietary fat from being absorbed. It is available both on prescription (120mg, three times daily with meals) and in a lower-dose over-the-counter form. It is not as potent as semaglutide but is well-established, with decades of safety data. For some patients, especially those with a lower BMI or those for whom injectable treatments are contraindicated, orlistat represents a sensible and accessible starting point. You might also explore XLS Medical Direct Fat Binder sachets as a complementary support option alongside dietary changes.

• Mounjaro (tirzepatide) is a dual GLP-1/GIP agonist showing impressive weight loss results
• Orlistat is the only licensed oral weight loss prescription medication in the UK
• Over-the-counter options like XLS Medical can support a calorie-controlled diet
• Behavioural interventions and structured diet programmes remain cornerstones of treatment
• Always access alternatives through a registered UK prescriber or pharmacy to ensure safety

Common Side Effects and How to Manage Them

Understanding side effects is one of the most practical things you can do before starting any new treatment. People searching for Wegovy tablets often encounter alarming anecdotes online, but the reality is that most side effects are manageable, temporary, and far less severe than the long-term health consequences of untreated obesity. Knowing what to expect helps you stick with the treatment through the initial adjustment period and get the most out of your prescription.

The most frequently reported side effects with semaglutide are gastrointestinal. Nausea is the most common, affecting a significant proportion of users, particularly in the early weeks as the dose is escalated. Vomiting, diarrhoea, constipation, and bloating are also reported. These symptoms tend to be most pronounced in the first four weeks after each dose increase and usually settle as the body adjusts. Eating smaller meals, avoiding fatty or heavily spiced foods, and staying well hydrated all help manage these effects effectively. Taking your injection on a consistent day each week and avoiding large meals close to injection time can also reduce gastrointestinal discomfort.

Less common but more serious side effects include pancreatitis, gallbladder problems, and in rare cases, hypoglycaemia if combined with other glucose-lowering medications. Any severe or persistent abdominal pain should be reported to a healthcare professional promptly. It is also worth noting that semaglutide can slow the absorption of oral medications due to its effect on gastric emptying — so if you take any other regular medicines, this should be discussed with your prescriber. For any gastrointestinal discomfort during treatment, some patients find that managing reflux symptoms with appropriate support, such as reviewing their diet or discussing options with a pharmacist, helps them stay on course with treatment.

• Nausea is the most common side effect and is usually temporary
• Eating smaller portions and avoiding fatty foods reduces gastrointestinal discomfort
• Severe abdominal pain should always be assessed by a healthcare professional
• Semaglutide may slow absorption of other oral medications — disclose all medicines to your prescriber
• Most side effects improve after the initial dose-escalation phase

Comparison of UK Weight Loss Medications in 2026

Medication	Active Ingredient	Form	Frequency	Average Weight Loss	Prescription Required
Wegovy	Semaglutide 2.4mg	Subcutaneous injection	Once weekly	Up to 15% body weight	Yes
Mounjaro	Tirzepatide	Subcutaneous injection	Once weekly	Up to 20%+ body weight	Yes
Orlistat (Rx)	Orlistat 120mg	Oral capsule	Three times daily	5–10% body weight	Yes
Orlos / Alli (OTC)	Orlistat 60mg	Oral capsule	Three times daily	3–5% body weight	No (pharmacy-supervised)
XLS Medical Weight Loss Plus	Litramine IQP-G-002AS	Tablet	Three times daily	Modest (supplement)	No
Rybelsus	Semaglutide 3–14mg	Oral tablet	Once daily	Licensed for T2D only	Yes

Key Takeaways

• Wegovy tablets do not currently exist as a licensed UK weight loss product — Wegovy is an injectable semaglutide pen
• Oral semaglutide (Rybelsus) is licensed only for type 2 diabetes in the UK, not for weight management
• Semaglutide works by mimicking GLP-1, reducing appetite, slowing digestion, and reducing reward-driven eating
• Clinical trials show Wegovy delivers approximately 15% average body weight reduction over 68 weeks
• Safe, effective alternatives — including Mounjaro and Orlistat — are available through registered UK prescribers and pharmacies

When to Seek Professional Advice

You should speak to a qualified healthcare professional before starting any weight loss medication, including semaglutide-based treatments. This is particularly important if you have any pre-existing medical conditions, take regular prescription medications, or have a history of eating disorders, pancreatitis, or thyroid problems. A proper medical consultation ensures that the treatment is appropriate for you and that you have the support and monitoring you need throughout your journey.

Seek urgent medical attention if you experience any of the following while taking semaglutide: severe and persistent abdominal pain (especially if it radiates to the back), unexplained rapid heartbeat, vision changes, signs of a severe allergic reaction such as facial swelling or difficulty breathing, or prolonged vomiting that prevents you from keeping fluids down. These symptoms can indicate rare but serious complications and should never be dismissed.

If you are unsure whether you qualify for Wegovy or another prescription weight loss treatment, an online consultation with a GPhC-registered prescribing pharmacist is a convenient and clinically appropriate first step. Services like those offered at Cured Pharmacy allow you to complete a detailed medical assessment from home, with your information reviewed by a qualified professional before any prescription is issued. You can also explore options like Formoline L112 tablets as a supplement-based bridge option while awaiting your consultation.

Scientific References

1. NICE Technology Appraisal TA875: Semaglutide for managing overweight and obesity — National Institute for Health and Care Excellence (NICE), 2023
2. MHRA Regulatory Approval of Wegovy (Semaglutide): Overview — Medicines and Healthcare products Regulatory Agency (MHRA)
3. Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Trial) — The Lancet, 2021

Frequently Asked Questions

How long does Wegovy take to show weight loss results?

Wegovy typically begins showing noticeable weight loss results within 4 to 8 weeks of starting treatment. Most clinical trials show meaningful weight reduction at 12 weeks, with the greatest results seen after 68 weeks of consistent use alongside a reduced-calorie diet and increased physical activity.

Is Wegovy safe to use long term?

Wegovy is considered safe for long-term use when prescribed and monitored by a qualified healthcare professional. Clinical data from the STEP trials demonstrates sustained tolerability over 68 weeks. As with any prescription medication, regular reviews with your prescriber are recommended to ensure continued suitability and monitor any side effects.

Can you take Wegovy with other weight loss supplements?

You should not combine Wegovy with other weight loss supplements without first consulting your prescriber. Some over-the-counter products may interact with semaglutide or increase the risk of side effects. Always disclose every supplement you take during your medical consultation to ensure your treatment plan is safe and appropriate for you.

What is the starting dose of Wegovy in the UK?

The starting dose of Wegovy in the UK is 0.25mg semaglutide injected once weekly for the first four weeks. The dose is then gradually increased every four weeks, progressing through 0.5mg, 1mg, 1.7mg, and finally 2.4mg, which is the recommended maintenance dose for long-term weight management.